NEWTON, Mass.--(BUSINESS WIRE)--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Medical University of South Carolina (MUSC) Hollings Cancer Center has enrolled the first patient in a Phase 2 trial of neoadjuvant treatment with NOV-002 in combination with chemotherapy in patients with early-stage breast cancer. Alberto Montero, MD, Assistant Professor of Medicine, Division of Hematology-Oncology, is the Principal Investigator.
